The drug bortezomib effectively treats chronic graft-versus-host disease , a common and debilitating side effect from allogeneic hematopoietic stem cell transplants, a study has found. The trial showed that bortezomib provides better outcomes than existing treatments and does not impair the immune response against residual cancer cells, or the graft-versus-tumor effect .
http://www.sciencedaily.com/releases/2014/10/141025215651.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine%2Fcancer+%28Cancer+News+--+ScienceDaily%29
http://www.sciencedaily.com/releases/2014/10/141025215651.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine%2Fcancer+%28Cancer+News+--+ScienceDaily%29
No comments:
Post a Comment